Navigation Links
Simulated model of eye's 3D structure facilitates stem cells transplant
Date:5/6/2014

Orlando, Fla. Scientists have developed a model that mimics the complex structure of the cornea to enable the transplant of healthy corneal stem cells. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando Fla.

Used to restore sight, corneal stem cells live in a specific physical environment. Transplanting these stem cells requires accurate mimicry of their natural surroundings during transport. In this work, vision scientists have recreated the 3D architecture where corneal stem cells naturally reside.

The cornea is the transparent window at the front of the eye. When the outermost cell layer of the cornea is damaged, vision is severely impaired. Treatment can include a transplant of healthy corneal stem cells to replace the lost cells.

Abstract Title: Tissue engineering the human limbal crypts: further characterization of an in vitro model

Presentation Start/End Time: Monday, May 5, 3:45 4pm
Location: S 331A-D
Session Number: 271


'/>"/>

Contact: Katrina Norfleet
knorfleet@arvo.org
240-221-2924
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Page: 1

Related biology news :

1. Daydreaming simulated by computer model
2. Initial research: Mangos effects on ulcerative colitis & bone parameters in animal models
3. 7.0T NMR assesses changes in hippocampal neurons in animal models of Alzheimers disease
4. N-glycan remodeling on glucagon receptor is an effector of nutrient-sensing by HBP
5. Loss of memory in Alzheimers mice models reversed through gene therapy
6. New mouse model could revolutionize research in Alzheimers disease
7. Development of new cell models that report circadian clock function
8. Gothenburg scientist in Nature: Climate models underestimate costs to future generations
9. New epidemiology model combines multiple genomic data
10. Friedreichs ataxia -- an effective gene therapy in an animal model
11. Math modeling integral to synthetic biology research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... ALAMEDA, Calif. , Dec. 8, 2016  Singulex, ... Single Molecule Counting technology, entered into a license and ... in serving science. The agreement provides Singulex access to ... Europe is used to diagnose ... the United States to aid in assessing ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... (PRWEB) , ... January 20, ... ... in Less Exposure Surgery (LES®) Technologies, announced today the next evolution in ... Pedicle Screw System platform). In contrast to the competition, SpineFrontier is focused ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi ... device open-access capability and technology platform, today announced ... leading biology focused preclinical drug discovery contract research ... will become a wholly-owned subsidiary of WuXi, and ... competences and providing greater services. The acquisition will ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
Breaking Biology Technology: